

## **UNIVERSITY OF MIAMI**

### **Curriculum Vitae**

**1. Date:** **January, 2013**

#### **I. PERSONAL**

**2. Name:** Bach Ardalán, M.D.

**6. Current Academic Rank:** Professor of Medicine and  
Molecular & Cellular Pharmacology (Tenure)

**7. Primary Department:** Department of Medicine

**8. Secondary or Joint Department**

**9. Citizenship:** USA

**10. Visa Type (if non-citizen)** None

#### **I. HIGHER EDUCATION**

11. Institutional (Institution; degree; date conferred)  
King's College, London, England, M.D. – 1969

12. Non-Institutional (description; dates) None

13. Certifications, licensure (description; board or agency; dates):  
Licenses: Florida Board of Medicine: ME 0059464  
California, - active  
British Columbia, Canada, Virginia (inactive)  
MRCP (UK)

#### **III. EXPERIENCE**

14. Non-Academic (employers; title; responsibilities; dates)None

15 Military (branch; rank; responsibilities; dates): None

16. Non-Academic (employers; title; responsibilities; dates)

7/1971-12/1971 King's College Hospital House Officer, General Medicine  
1/1972-06/1972 Eastbourne General House Officer, General Surgery

7/1972-6/1973 King Edward Mem. Hosp Senior House Officer, Medicine

7/1973- 6/1974 Royal Marsden Hospital - Registrar, General Medicine

7/1974-6/1975	St. Charles Hospital - Registrar, General Medicine
7/1975-3/1976	Royal Post-Graduate Medical School - Registrar, Leukemia, Hematology
3/1976-6/1976	Cancer Control Agency of British Columbia Locum Assistant Professor Medical Oncology
7/1976-6/1979	National Cancer Institute Clinical Biochemist, Biochemistry
7/1976-6/1979	Georgetown University -Medical Oncology, Fellowship
7/1979-6/1981	City of Hope Natl. Med. Staff Center, Medical Oncology Physician, Researcher
7/1981-6/1987	USC School of Medicine, Div. Of Medical Oncology USC Comprehensive Cancer Center Asst. Professor of Medicine
6/1987-7/1994	University of Miami School of Medicine Department of Medicine Division of Hematology/Oncology Sylvester Comprehensive Cancer Center Associate Professor
7/1994 - Present	University of Miami School of Medicine Department of Medicine Division of Hematology/Oncology Sylvester Comprehensive Cancer Center Professor

17. Military (branch; rank; responsibilities; dates): None.

#### IV. PUBLICATIONS

18. Books and monographs published: None

19. Juried or refereed journal articles and exhibitions:

1. Dowd PM, **Ardalan B**, Overall JD. Unusual cutaneous associations of a malignant carcinoid tumor of the bronchus-erythema annulare centrifugum and white banding of the toe nails. Brit J Derm 1975 Sep;93(3)341-345

2. **Ardalan B**, Lewis SM, Catovsky D, Hows JM: Splenic red cell pooling in hairy cell leukemia. Brit J Haemat 1977Mar;35(3); 351-7
3. **Ardalan B**, Buscaglia MD, Schein PS: Tumor-5-fluorodeoxyridylate concentration as a determinant of 5-fluorouracil response. Biochem Pharmacol 1978;27(16):2009-2013.
4. **Ardalan B**, MacDonald JS, Cooney DA, Schein PS: Study on mechanisms of 5-fluorouracil resistance in murine and human tumors. Bull Cancer 1979;(Paris) 66(1):55-59.
5. Herman EH, **Ardalan B**, Beir C, Waravdekar VS, Krop S: Reduction of danorubicin (NSC 82151) lethality and myocardial cellular alterations by pretreatment with ICRF 187 (NSC 169,780) in Syrian golden hamsters. Cancer Treat Rep 1979 Jan;63(1):89-92.
6. **Ardalan B**, Cooney DA, MacDonald JS, Glazer R, Jayaram HN, Carrico CK, Schein PS: Mechanisms of sensitivity and resistance of murine tumors to 5-fluorouracil. Cancer Res 40:1431-1437,1980.
7. Herman E, **Ardalan B**, Jordan W, Zaharko D, Bolton B, Cooney DA: Toxicologic effects of high dose thymidine in mice. Toxicol Appl Pharmacol 1980 Dec;56(3) 443-446,
8. Kensler T, Erlichman C, Jayaram HN, Tyagi A, **Ardalan B**, Cooney DA: Peripheral leucocytes as indicators of the enzymic effect of N-(phosphonacetyl)-L-Aspartic acid on human L-aspartate transcarbamylase (ATCase) activity. Cancer Treat Rep 1980 Aug-Sep;64(8-9):967-73.
9. **Ardalan B**, MacDonald J, Cooney D, Lippman M, Schein P: Prediction of clinical response to 5-FU containing chemotherapy: Preliminary results of in vitro assay in human breast cancer. Recent Results Cancer Research, 1980; 74:84-90 (Edited by G. Mathe and F. Muggia), Springer-Verlag, Heidelberg,
10. **Ardalan B**, Cooney D, MacDonald J: Physiological and pharmacological determinants of sensitivity and resistance to 5-fluorouracil in lower animals and man. Advances in Pharmacology and Chemotherapy, 1980;17:289-321 (Edited by Garattini, A. Goldin, F. Hawking, and I.J. Koplin), Academic Press New York.
11. **Ardalan B**, Kensler T, Jayaram HN, Morrison B, Choie D, Chadwick M, Loss R, Cooney DA: Long-term association of PALA with bone. Cancer Res 1981 Jan;41(1):150-6.
12. Kensler T, Hankerson J, Mutter G, Jayaram H, **Ardalan B**, Tyagi A, Cooney DA: Mechanism of resistance of variants of the Lewis lung carcinoma to N-(phosphonacetyl)-L-Aspartic acid. Cancer Res 1981 Mar;41(3):894-904.
13. **Ardalan B**, MacDonald JS, Cooney D, Lippman M, Schein P: The potential for clinical application of in vitro assays predicting 5-FU sensitivity in man. Cancer Treat Rep. 1981;65 Suppl 3:57-61.
14. **Ardalan B**, Glazer R: An update on the biochemistry of 5-fluorouracil. Cancer Treat Rev. 1981 Sep;8(3):157-167.
15. **Ardalan B**, Glazer RL, Kensler T, Jayaram HN, Pham T, MacDonald JS, Cooney DA: Synergistic effect of 5-fluorouracil and N-(phosphonacetyl)-L-Aspartate on cell growth in a human mammary carcinoma cells. Biochem

- Pharmacol.1981 Aug 1;30(15): 2045-2049.
16. Herman EH, Ferrans VJ, Jordan W, **Ardalan B**: Reduction of chronic daunorubicin cardiotoxicity by ICRF-187 in rabbits. Res Comm Chem Path Pharmacol.1981 Jan;31(1):85-97.
  17. Jayaram HN, Kensler TW, **Ardalan B**: Radiometric enzyme-inhibition technique for measuring acivicin in plasma. Cancer Treat Rep.1981 May-June;65(5-6):491-4
  18. **Ardalan B**, Arakawa M, Villacorte D, Jerome HN, Coney DA: Effect of L-glutamine antagonists on 5-phosphoribosyl 1-pyrophosphate levels in P388 leukemias and murine colon adenocarcinomas in vivo. Biochem Pharm 1982 Apr 15;31(8)1509-13.
  19. **Ardalan B**, Villacorte D, Heck D, Corbett T: Phosphoribosyl pyrophosphate, pool size and tissue levels as a determinant of 5-fluorouracil response in murine colonic adenocarcinomas. Biochem Pharm 1982 Jun 1;31(11):1989-92.
  20. **Ardalan B**, Jerome HN, Johnson RK: Collateral sensitivity to N-(Phosphonacetyl)-L-aspartic acid in a line of P388 leukemia cells selected for resistance to L-(alpha S, 5S)-alpha-amino-3-chloro-4, 5-dihydro 5-isoxazoleacetic acid (Acivicin). Cancer Res 1983 Apr;43(4): 1598-601.
  21. Presant CA, **Ardalan B**, Bulthauf P, Chan C, Staples R, Green L, Browning S, Carr I, Chang F, Thayer W: Continuous five-day infusion of PALA and 5-FU: A Pilot Phase II Trial. Med Ped Oncology 1983;11(3):162-163.
  22. Chandrasekaran , **Ardalan B**: High performance liquid chromatographic determination of 2-beta-D-ribofuranosylthiazole-4-carboxamide in urine and plasma. Journal of Chromatography 1983 Aug 12;276(1):237-242.
  23. Chandrasekaran B, **Ardalan B**:Separation of ribose-5-phosphatase, ribose-1-phosphate deoxyribose-1-phosphate by high performance liquid chromatography and spectrophotometric determination using 2-cyanoacetamide. Analytical Letters 16:1265-1277, 1983.
  24. **Ardalan B**, Jamin D, Jerome HN, Presant C: Phase I study of continuous-infusion PALA and 5-FU. Cancer Treat Rep 1984 Mar;68(3):531-4.
  25. Chandrasekaran B, **Ardalan B**: Determination of 3-deazaguanine in mice plasma by high-performance liquid chromatography. Journal of Chromatography 1984 Aug 10;309(2):403-408.
  26. Herman EH, El-Haage AN, Ferrans VJ. **Ardalan B**: Comparison of the severity of the chronic cardiotoxicity produced by doxorubicin in normotensive and hypertensive rats. Toxicology and Applied Pharmacology 1985 Apr;78(2):202-214.
  27. Jerome HN, **Ardalan B**, Deas M,Johnson R: Mechanisms of resistance of a variant of P388 leukemia to L-(alpha) S,5S)-alpha-amino-3-chloro-4,5-dihydro-5-isoxazoleacetic acid (acivicin). Cancer Research 1985 Jan;45(1):207- 12.
  28. McGovern P, Pratt EA, Belt RJ, Taylor SA, Benjamin RA, **Ardalan B**, Ohnuma T: Pharmacokinetic and biochemical studies on acivicin in Phase I clinical trials. Cancer Res 1985 Sep;45(9):4460-4463.
  29. **Ardalan B**, Chandrasekaran B, Hrishikeshavan HJ: Biochemical mechanisms for the schedule synergism of (alpha S,5S)-2 amino-3-chloro-4,5-dihydro-5-

- isoxazoleacetic acid and 5-fluorouracil in P388 leukemia. Cancer Chemotherapy Pharmacology 1985;15(1):44-48. Sarna G, Pertcheck M, Figlin R, **Ardalan B**: Phase I study of recombinant beta ser 17 interferon in treatment of cancer. Cancer Treatment Report 1986 Dec;70 (12):1365-1372.
30. **Ardalan B**, Paget GE: Mechanism of action of a new antitumor agent, carbetimer. Cancer Res 1986 Nov;46(11);5473-5476.
  31. Spicer D, **Ardalan B**, Daniels JR, Silberman H, Johnson K: Re-evaluation of the maximum tolerated dose of continuous infusion of 5-fluorouracil with pharmacokinetics. Cancer Res 1988 Jan 15, 48(2):459-461.
  32. Singh G, **Ardalan B**: Studies on the mechanism of 3-deazaguanine cytotoxicity in L1210-sensitive and -resistant cell lines. Cancer Chemo Pharm 1988;22(3):191-196.
  33. Mitchell SM, Mitchell JK, Grunberg SM, **Ardalan B**, Kempf AR, Olson C, Monuki E, Shau H: Immunological effect of 4-hour infusions of recombinant interferon-beta 17-ser in cancer uptightness. Cancer Res (Submitted).
  34. **Ardalan B**, Singh G, Silberman H: A randomized Phase I-II study of short-term infusion of high-dose 5-fluorouracil with or without N-(Phosphonacetyl)-L-Aspartic acid in patients with advanced pancreatic and colorectal cancers. Journal of Clin Oncol 1988 Jun; 6(6):1053-1058.
  35. **Ardalan B**, Waldman S, Sklaver L: The pyrimidine antagonists:5-fluorouracil and floxuridine (Book-Chapter in Cancer Chemotherapy by infusion, Edited by Jacob J. Lokich, M.D.) 2nd edition, Precept press, Inc., Chicago, Page 85-121, 1990.
  36. Morrell LM, **Ardalan B**, Richman SP, Fleming TR, MacDonald JS: A Phase II multi-institutional trial of low dose N-(Phosphonacetyl)-L-Aspartate and high dose 5-Fluorouracil as a short-term infusion in the treatment of adenocarcinoma of the pancreas, A SWOG Study. Cancer 67:363-366, 1991.
  37. **Ardalan B**, Chua L, Tian E, Reddy R, Sridhar KS, Benedetto P, Richman S, Legaspi A, Waldman S, Morrell L, Feun L, Savaraj N, Livingstone A: A Phase II study of weekly 24 hour infusion with high dose 5-fluorouracil (5-FU) with leucovorin (LV) in colorectal carcinoma. Journal of Clin Oncol 1991 Apr;9(4)625-630.
  38. Serafini AN, Vargas-Cuba R, Benedetto P, Legaspi A, Feun L, Robinson D, **Ardalan B**, Dewanjee MK, Sevin BU, Averette H, Sfakianakis G: Clinical experience in utilizing radiolabeled monoclonal antibodies. Antibody, immunoconjugates, -pharmaceuticals 4:77-83, 1991
  39. **Ardalan B**, Sridhar K, Benedetto P, Richman S, Waldman S, Morrell L, Feun L, Savaraj N, Livingstone A: Phase I and II study of high dose 5-fluorouracil and high dose leucovorin with low dose Phosphonacetyl-L-Aspartic Acid in patients with advanced malignancies. Cancer. 1991 Sep 15; 68(6):1242-1246.
  40. Serafini AN, Vargas-Cuba R, Benedetto P, **Ardalan B**, Garrido J, Robinson D, Moffat F, Pinsky CM: Technetium-99m Labeled Fab fragment of anti-CEA monoclonal antibody for the radioimmunodetection of colorectal adenocarcinoma. Antibody, Immunoconjugates, and Radiopharmaceuticals

- 4:561-568, 1991.
41. **Ardalan B**, Hussein A, Shanahan W Jr., Shields M: Carbetimer: A reevaluation of a drug with a novel mechanism of action. Cancer Treatment Reviews 1991 Mar;18(1):73-83.
  42. Sridhar KS, Hussein AM, Benedetto P, Waldman S, Feun LG, Savaraj N, **Ardalan B**, Desai P: A Phase II trial of mitoxantrone in head and neck carcinoma. Am Journal Clin Oncol 1991 Aug; 14(4): 298-304.
  43. Hung SSJ, **Ardalan B**: Metastasis-induced acute pancreatitis. West Journal Med 1991 Aug;155(2):176-178.
  44. **Ardalan B**, Sridhar KS, Reddy R, Benedetto P, Richman S, Waldman S, Morrell L, Feun L, Savaraj N, Livingstone A: Phase I study of high dose 5-fluorouracil and high dose leucovorin with low dose Phosphonacetyl-L-Aspartic Acid in patients with advanced malignancies. Intl Journal of Radiation Oncology Biology Physics. 1992;22(3)511-514
  45. Sridhar KS, Hussein AF, Benedetto P, **Ardalan B**, Savaraj N, Richman SP: Phase II trial of 4'-O-tetrahydropyranyl-adriamycin (Pirarubicin) in head and neck carcinomas, Cancer, 1992 Sep 15;70 (6)1591-1597.
  46. Ucar A, **Ardalan B**: Biochemical modulation of fluoropyrimidines. Journal of Infusional Chemotherapy, Volume 3, 174-183, 1993.
  47. Sridhar KS, Krishan A, Samy TSA, Sauerteig A, Wellham LL, McPhee G, Duncan RC, Anac SY, **Ardalan B**, Benedetto PW. Prochlorperazine as a doxorubicin-efflux blocker: phase I clinical and pharmacokinetics studies. Cancer Chem Pharm 1993;31(6): 423-430.
  48. **Ardalan B**, Flores M: A new complication of permanent indwelling central venous catheters using high-dose fluorouracil and leucovorin. J Clin Oncol 1993 Feb;11(2): 384.
  49. Feun LG, Savaraj N, Reddy R, Jeffers L, Benedetto P, Livingstone AS, **Ardalan B**, Levi JV, Parker T. A phase II trial of recombinant leukocyte interferon plus doxorubicin in patients with hepatocellular carcinoma. American J of Clinical Oncology 1994 Oct;17 (5):393-5.
  50. **Ardalan B**, Ucar A, Reddy R, Livingstone AS, Markoe A, Schwade J, Richman SP, Donofrio K. Phase I trial of low dose N-phosphonacetyl-L-aspartic acid and high dose 5-fluorouracil administered concomitantly with radiation therapy for unresectable localized adenocarcinoma of the pancreas. Cancer 1994 Oct 1;74 (7): 1869-1873.
  51. Moffat FL, Jr., Vargas-Cuba RD, Serafini RN, Casillas VJ, Morillo G, Benedetto P, Robinson DS, **Ardalan B**, Manten HD, Clark KC: Radioimmuno-detection of colorectal carcinoma using technetium-99m-labeled Fab fragments of the IMMU-4 anti carcinoembryonic antigen antibody. Cancer 1994 Feb 1; 73 (3 Suppl): 836-845.
  52. **Ardalan B**, Flores MR. A new complication of chemotherapy administered via permanent indwelling central venous catheter. Cancer 1995 April 15;75 (8):2165-8.
  53. Leichman CG, Fleming TR, Muggia FM, Tangen CM, **Ardalan B**, Doroshow JH, Meyers FJ, Holcolombe RF, Weiss GR, Mangalik A, Macdonald JS. Phase

- II study of fluorouracil and its modulation in advanced colorectal cancer: A Southwest Oncology Group Study, J Clin Oncol 1995 Jun 13 (6):1303-1311.
54. Martino RL, Fleming Tr, Morrell LM, **Ardalan B**, Richman SP, Macdonald JS. Phase II trial of low dose N-(phosphonacetyl)-disodium L-aspartic acid and high dose 24 hour infusion 5-Fluorouracil in advanced gastric adenocarcinoma: A southwest oncology group study. Investigational New Drugs.1996; 14 (4): 419-21.
  55. **Ardalan B**. Gastric Cancer. Cancer Control 1998 May; 5 (3 Suppl 1) 34-36.
  56. **Ardalan B**. Raez, Luis, Merchan, Jaime, Franceschi, Dido. Biomodulation of Fluorouracil in Colorectal Cancer. Cancer Investigation 1998; 16(4) 237-251.
  57. Feun LG, Reddy KR, Scagnelli T, Yrizarry JM, Guerra JJ, Russell E, Schwartz, M, Savaraj N, Livingston AS, Levi JU, Jeffers LJ, **Ardalan B**, Schiff ER. A phase I study of chemoembolization with cisplatin, thiotepa, and lipiodol for primary and metastatic liver cancer. AM J Clin Oncol 22,(4):375-380, 1999.
  58. Bathe OF, Franceschi D, Livingstone AS, Moffat, FL, Tian E, **Ardalan B**. Increased thymidylate synthase gene expression in liver metastases from colorectal carcinoma: Implications for chemotherapeutic options and survival. Cancer J Sci Am 1999 Jan-Feb; 5(1): 34-40.
  59. Subbarayan PR, Sarkar M. **Ardalan B**. Isolation of genomic DNA from human whole blood. Biotechniques. 2002 Dec;33 (6):1231,1234.
  60. Feun L, O'Brien C, Molina E, Rodriguez M, Jeffers L, Schiff ER, Marini A, Savaraj N, **Ardalan B**. Recombinant leukocyte interferon, doxorubicin, and 5 FUdR in patients with hepatocellular carcinoma – A phase II trial. J Caner Res Clin Oncol, 2003 Jan; 129(1):17-20.Epub 2003 Jan 09.
  61. Patel M, Ardalan K, Hochman I, Tian EM, **Ardalan B**. Cytotoxic effects and mechanisms of an alteration in the dose and duration of 5-fluorouracil. Anticancer Res. 2003 Jan-Feb; 23(1A): 447-452.
  62. Whitehead RP, Benedetti JK, Abbruzzese JL, **Ardalan B**, Goodwin JW, Balcerzak SP, Samlowski WE, Lenz HJ, Macdonald JS. A phase II study of high-dose 24 hour continuous infusion 5-FU and leucovorin and low-dose PALA for patients with advanced pancreatic adenocarcinoma: A Southwest Oncology Group Study. Invest New Drugs. 2004 Aug; 22(3): 335-341.
  63. Whitehead RP, Benedetti JK, Abbruzzese JL, **Ardalan B**, Williamson S, Gaynor ER, Balcerzak, SP, Macdonald JS. A phase II pilot study of high-dose 24-hour continuous infusion of 5-FU and leucovorin and low-dose PALA for patients with colorectal Cancer: A Southwest Oncology Group Study. Investigational New Drugs 22: 467-473, 2004
  64. L.Paley, V. Malinovskii, S.R. Pochi, **B. Ardalan** and T. J. Lampidis. Hypoxia inducible transcriptional factor-1a is associated with mitosis under normoxia and hypoxia. The Miami Nature Biotechnology winter symposia, Miami FL. 2004 (<http://www.med.miami.edu/mnbws/Malinovskii-.pdf>)
  65. Subbarayan PR, M. Sarkar, G. Nelson, E. Benitez and **B. Ardalan**. Cyclin B1 mediated G2/M DNA damage checkpoint is affected in 5FU resistant colorectal cancer HT29 cells. 2004. The Miami Nature Biotechnology winter symposia, Miami, FL. (<http://www.med.miami.edu/mnbws/Pochi-.pdf>)

66. K. Ferry, **Ardalan B**, D. Franceschi, B. Gogel, M Sundaram, I Kaklamanos, A Livingstone -Esophageal Carcinoma: Current Controversial Topics.-Cancer Inv. Vol.22, No. 6, pp. 886-901, 2004
67. Manish Patel, Ram Agarwal, **Ardalan B**. Effects of oxaliplatin and CPT-11 on cytotoxicity and nucleic acid incorporation of the fluoropyrimidines. J. Cancer Res Clin Oncol 130:453-459, 2004
68. **Ardalan B**, Mayra Lima. A phase II trial of FUdR in patients with advanced pancreatic cancer. J. Cancer Res Clin Oncol 130: 561-566, 2004
69. Alfonso Ribeiro, M.D., Dido Franceschi, M.D., Javier Parra, M.D., Alan Livingstone, M.D., Marya Lima, M.S.N,A.R.N.P, Kara Hamilton-Nelson, M.PH., and **Bach Ardalan,M.D**, Endoscopic Ultrasound Restaging After Neoadjuvant Chemotherapy in Esophageal Cancer – American Journal of Gastroenterology 1572-0241, 2006
70. Nouri K, Ricotti CA, Bouzari N, Chen H, Ahn E, **Bach Ardalan, MD**, Jordan-Mcmurry I, Ayalla E, Lee K. High incidence of recurrent herpes simplex and herpes zoster infection during treatment with arsenic trioxide: Report of cases. J Drugs Dermatology 2006 5 (2): 182-185
71. Subbarayan PR\*, Lima M and **Ardalan B** (2006), Arsenic trioxide/ascorbic acid therapy in patients with refractory metastatic colorectal carcinoma: A clinical experience, *Acta Oncologica*. 2007;46(4):557-61(<http://www.journalsonline.tandf.co.uk/openurl.asp?genre=article&id=doi:10.1080/02841860601042456>).
72. A Phase II study of irinotecan, high-dose 24-hours continuous intravenous infusion of floxuridine and leucovorin (IFLUX) for advanced, previously untreated colorectal cancer. **Bach Ardalan, MD**, Olga Kozyreva, MD, Kao-Tai Tsai, PhD, Edgardo S. Santos, MD, Dido Franceschi, MD, Alan Livingstone, MD, Mayra Lima, MSN- Anti-Cancer Drugs, 2007 Sep;18 (8)::955-961
73. Neoadjuvant, Surgery, and Adjuvant Chemotherapy without Radiation for Esophageal Cancer. **B Ardalan, MD**; Seth A. Spector, MD; Alan S. Livingstone, MD; Dido Franceschi, MD; Dmitry Mezentsev, MD; Mayra Lima, ARNP; Carol P. Bowen-Wells, MD; Lynne Sparling, RN; Eli Avisar, MD; Gail Walker, PhD; Parvin Ganjei-Azar, MD; Japanese Journal of Clinical Oncology. 2007 Aug 18
74. O. N Kozyreva, D. Mezentsev, **B. Ardalan**, A. Livingstone – Diagnosis in Oncology Asymptomatic Muscle Metastases from Esophageal Adenocarcinoma - Journal of Clinical Oncology . 2007 Aug 20; Vol 25 (24) 3780-3793.
75. Subbarayan PR\*, Wang PG, Lampidis TJ, **Ardalan B**, and Braunschweiger Differential expression of Glut1 mRNA and protein levels correlates with increased sensitivity to the glyco-conjugated nitric oxide donor (2-glu-SNAP) in different tumor cell types. J. Chemotherapy. 2008 Feb;20(1):106-11
76. **Ardalan B**, Subbarayan PR, Ramos Y, Gonzalez M, Fernandez A, Mezentsev D, Reis I, Duncan R, Podolsky L, Lee K, Lima M, Ganjei-Azar P, A Phase I



Study of 5-FU (plus Leucovorin) and Arsenic Trioxide for Patients with Refractory/Relapsed Metastatic Colorectal Carcinoma. *Clinical Cancer Research* 2010 Jun 1;16(11):3019-27

77. **Subbarayan PR**, Lee K and Ardalan B Arsenic trioxide suppresses thymidylate synthase in 5-FU resistant colorectal cancer cell line HT29 (HT29FU) in vitro re-sensitizing cells to 5-FU. *Anti Cancer Research* 2010 Apr;30 (4): 1157-62.
78. **Subbarayan PR**, Sarkar M, G. Nelson G, Benitez E and Ardalan B, Chronic exposure of colorectal cancer cells to fluoropyrimidine analogues in vitro induces thymidylate synthase and suppresses p53. A molecular explanation for the mechanism of 5-FU resistance. *Anti Cancer Research* 2010 Apr;30(4):1149-56
79. **B. Ardalan**, Pochi R. Subbarayan, Malancha Sarkar, Stefania Impellizzeri, Francisco Raymo, Balakrishna L. Lokeshwar, Pradeep Kumar, Ram P. Agarwal. Anti-proliferative and anti-cancer properties of *Achyranthes aspera*: Specific inhibitory activity against pancreatic cancer cells. et al., *Journal of Ethnopharmacology* 131 (2010) 78-82
80. **B. Ardalan**, Solomon N, Mezentsev D, Reis I, Lima M, Rios J, Avisar E, Franceschi D, Livingstone A, Podolsky L, A phase II study of neoadjuvant and adjuvant chemotherapy with 5fluorodeoxyuridine, leucovorin, oxaliplatin and docetaxel in the treatment of previously untreated advanced esophageal adenocarcinoma. *J Clin Oncol.* 2011 Apr, 41 (4): 469-76
81. **B. Ardalan**, Podolsky L, Oh M, Subbarayan PR, Franceschi D, Livingstone A, 5 Fluorouracil/Leucovorin and arsenic trioxide for patients with refractory/relapsed colorectal carcinoma: a clinical experience. *Acta Oncol.* 2011 May: 50 (4) 602-5
82. **B. Ardalan**, Hammad H, Sarkar M, Gupta N, Subbarayan PR. *Oncol Rep.* 2012 Jan;27(1):246-9. doi: 10.3892/or.2011.1469. Epub 2011 Sep The presence of three repeats in the 5' UTR region of thymidylate synthase (TS) is associated with increased TS mRNA expression in cultured human cancer cell lines in vitro.

## 20. Other works, publications and abstracts:

1. **Ardalan B**, Lewis MS:  $^{52}\text{Fe}$  versus  $^{59}\text{Fe}$  in detection of extramedullary erythropoiesis: Int Conf Hematol. London, U.K. 1975.
2. **Ardalan B**, Lewis MS: Splenic red cell pooling in hairy cell leukemia. Int Conf Hematology. London, U.K., 1975.

3. **Ardalan B**, Schein PS, Woolley, P: Biological parameters of 5-fluorouracil responsiveness in murine colonic tumors. AACR 18:895 (**224**), 1977.
4. **Ardalan B**, Cooney DA, Schein PS: A new in vitro predictive assay for response to 5-fluorouracil chemotherapy in murine and human tumors. AACR 18:115 (**460**), 1978.
5. Herman EH, **Ardalan B**: Modification of daunorubicin toxicity by pre-treatment with antineoplastic agent ICRF 187 and related compounds. Fed Am Soc Ex Biol 37:557, 1978.
6. **Ardalan B**, Cooney DA, Schein PS: A retrospective analysis of the mechanisms of resistance or sensitivity of murine and human tumors to 5-fluorouracil. AACR 20:214 (**868**), 1979.
7. Herman EH, **Ardalan B**: Reduction of chronic daunomycin toxicity by pretreatment with ICRF 187 in rabbits. Inter Congress Chemotherapy 2:868, 1979.
8. **Ardalan B**, Glazer R, Kensler T, Jayaram H, Cooney DA, MacDonald J: Biochemical mechanisms for the synergism of 5-fluorouracil (5-FU) and phosphonacetyl-L-aspartate (PALA) in human mammary carcinoma cells. AACR 1:8 (**32**), 1980.
9. Cooney DA, **Ardalan B**, Morrison W, Chadwick M, Liss R, Choie D,
10. Kensler TW, Jayaram HN: Long-term association of PALA with bone. AACR 21:9 (**33**), 1980.
11. Arakawa M, **Ardalan B**: Pharmacokinetics of FU as the determinant of its toxicity and antitumor activity in a murine colonic adenocarcinoma line. AACR 22:263 (**1042**), 1981.
12. Hiremagular N, Jayaram HN, **Ardalan B**, Deas MW, Cooney DA: Studies on the mechanism of action of DON 6-diazo-5-oxo-L-norleucine. AACR 22:251 (**994**), 1981.
13. Klein L, Presant C, Bulthauf P, Hill R, Metter G, Forman S, Bertrand M, Green L, Koehler S, Carr B, **Ardalan B**, Roach L, Pulone B: Velban (V) Infusion with combination chemotherapy (CT) as primary therapy of metastatic breast cancer. ASCO 22:444 **C437**, 1981.
14. Metter G, Presant CA, Ganteaume L, Bulthauf P, Klein L, Rappaport D, Bertrand M, Forman S, Koehler S, Green L, **Ardalan B**, Carr B, Chang FF: Randomized trial of amphotericin B (AmB) plus combination chemotherapy in non-small cell bronchogenic carcinoma (NSBC). ASCO 22:507 (**C681**), 1981.
15. Pham T, **Ardalan B**, Villacorte D, Corbett T, Benfield JR: Intracellular PRPP concentration and metabolism as a determinant of 5-fluorouracil response in murine colonic adenocarcinomas. AACR 22:30 (**121**), 1981.
16. Villarcorte D, **Ardalan B**, Arakawa M, Cooney DA, Jayaram HN: In vitro and in vivo effect of glutamine antagonists on PRPP metabolism in P288 leukemia and in murine colonic adenocarcinoma. AACR 22:30 (**122**), 1981.
17. Aiginer P, Kolbe H, Kuzmits R, Kuhbock J, Linkesch W, Spona J, **Ardalan B**: Prognostic value of alpha-1-fetoprotein, beta-human chorionic gonadotropin and ferritin in metastasized testicular cancer. ASCO 22:347 (**C59**), 1981.
18. Yi S, **Ardalan B**, Jayaram HN, Cooney DA, Marguez V, Johnson RK: Collateral sensitivity of PALA in P388 tumor rendered resistant to Acivicin. AACR 23:8 (**29**), 1982.
19. **Ardalan B**, Hutton K, Karle J, Hoerauf R, Jayaram HN, Presant CA: Serum uridine levels as the predictor of response in patients treated with 5-FU and PALA. AACR 23:8 (**30**), 1982.

20. Jayaram HN, Cooney DA, Dion RL, Glazer RI, **Ardalan B**, Robins RK, Johnson DG: Studies on the mechanism of action of the new 18-<sup>o</sup>ncolytic thiazole nucleoside, 2-b-Ribofuranosylthiazole-4-Carboxamide (NSC 286193). AACR 23:217 (**856**), 1982.
21. Chandrasekaran B, **Ardalan B**: High performance liquid chromatographic determination of 2-b-D ribofuranosyl thiazole-4-carboxamide in urine and plasma. AACR 24:291 (1149), 1983.
22. **Ardalan B**, Chandrasekaran B, Stolinsky D: Biochemical mechanisms for the scheduled synergism of Acivicin L-(S,5S)-□S, 5S-□amino-3-chloro-4, 5-dihydro-5-isoxazole-acetic acid and 5-fluorouracil in P388 leukemia. AACR 24:270 (1067), 1983.
23. Chandrasekaran B, **Ardalan B**: Analysis and quantitation of 3-deazaguanine in mice plasma by high performance liquid chromatography. AACR 25:356 (1413), 1984.
24. Spicer D, **Ardalan B**, Silberman H, Chandrasekaran B, Daniels J, Johnson K: Phase I trial of prolonged continuous intravenous infusion of 5-FU with pharmacokinetics. ASCO 3:41 (**C158**), 1984.
25. **Ardalan B**, Kotarac J, Hrishikeshavan HJ, Kibbe R, Paget GE: Studies on the mechanism of action of new antitumor polymer, Carbetimer. AACR 26:18 (70), 1985.
26. Hrishikeshavan HJ, **Ardalan B**, Ochiai R, Stolinsky D: In vitro effect of selenious acid and sodium thiosulphate on cisplatin toxicity in human and animal cell lines. AACR 26:262 (**1035**), 1985.
27. **Ardalan B**, Hrishikeshavan HJ, Bick A, Ehler E, Muir K, DeLap AJ, Grillo-Lopez, Whitfield L: Phase I pharmacokinetic study of 3-Deazaguanine. AACR 27:173 (686), 1986.
28. Hrishikeshavan HJ, **Ardalan B**, Paget GE: Inhibition of cyclic nucleotide phosphodiesterase by Carbetimer in a human melanoma. AACR 27:280 (1110), 1986.
29. Singh G, **Ardalan B**, Kempf R: Studies on the mechanism of 3-Deazaguanine cytotoxicity in L1210 sensitive and resistant cell lines. AACR 27:387 (1535), 1986.
30. Luna MC, **Ardalan B**, Orczyk G: Studies on the mechanism of Carbetimer induced hypercalcemia. AACR 28:443 (1758), 1987.
31. Chan KK, **Ardalan B**, Hong PS, Barrientos A, Luna MC: Gas Chromatographic-Electrolytic (GC-ELC) and Mass Spectrometric (GC-MS) assays of Clomesone and its pharmacokinetics in the mouse and rat. AACR 28:434 (7212), 1987.
32. **Ardalan B**, Singh G: A randomized Phase I-II study of short-term infusion of high-dose 5-fluorouracil with or without(phosphonacetyl)-L-aspartic acid in patients with advanced pancreatic and colorectal cancers. ASCO 6:81 (314), 1987.
33. Hepburn M, **Ardalan B**, Shanahan W, Shield M, Richman S: Differentiating properties of Carbetimer, a new antineoplastic agent. AACR 29:514 (2043), 1988.
34. **Ardalan B**, Hepburn M, Shanahan W, Shield M, Richman S: Carbetimer, a new antimetastatic agent with antimetastatic properties. AACR 29:501 (1991), 1988.
35. Garty J, Serafini A, **Ardalan B**, Fayed F, Jabir AM, Benamar M, Goldenberg D: Scintigraphic detection of colorectal carcinoma by using I-123 labelled Fab and F(ab)<sup>1</sup><sub>2</sub> Fragments of anti-CEA antibodies NP-4. Radiological Society of North America. December, 1988.
36. Hussein A, **Ardalan B**, Sklaver L, Reddy R, Savaraj N, Waldman S, Richman S, Feun L, Hung S, Benedetto P, Sridhar KS: Chemotherapy (C) of advanced carcinoma with 5-Fluorouracil and leucovorin (LV). ASCO 8:116 (449), 1989.

37. Lemus J, **Ardalan B**, Pei Z, Shanahan W, Gardiner P, Shield M: Protection of adriamycin induced acute toxicity by pretreatment with a new antineoplastic agent, Carbetimer (CBT) AACR 30:564 (2244), 1989.
38. **Ardalan B**, Hussein A, Shanahan W, Aspinall R, Gardiner Shield M, Richman S, Sridhar KS, Benedetto P, Feun L, Waldman S, Glantz A, Sklaver L: Phase I continuous intravenous (IV) infusion of carbetimer (CBT) in refractory malignancies. AACR 30:283 (1125), 1989.
39. Chua L, **Ardalan B**, Sridhar KS, Hussein A, Richman S, Robinson D, Livingstone A: A Phase II study of short term protracted infusion with high dose 5-fluorouracil (5-FU) with leucovorin (LV) in colorectal carcinoma. ASCO 9:104 (401), 1990
40. **Ardalan B**, Cotterell A, Shanahan W, Aspinall R, Gardiner P: Protection of Adriamycin (AD) induced acute toxicities by pre-treatment with carbetimer (CBT). AACR 31:446 (2653), 1990.
41. **Ardalan B**, Sridhar KS, Hussein A, Legaspi A, Barmann A: Double biochemical modulation of 5-fluorouracil (5FU) with phosphonacetyl-L-aspartic acid (PALA) and leucovorin (LV): A phase I study. ASCO 9:104 (140), 1990.
42. Sridhar KS, Hussein AM, Barmann A, Benedetto P, **Ardalan B**, Waldman S, Richman S, Feun L, Savaraj N, Morrell L, Donnelly E: Phase II study of q 3 week IV bolus Pirarubicin (4'-0-tetrahydropyranyl-adriamycin) in head and neck carcinoma. ASCO 9:179 (694), 1990.
43. Serafini AN, Vargas-Cuba R, Benedetto P, **Ardalan B**, Legaspi A, Robinson D, Garrido J, Perez L, Sfakianakis GN, Pinsky C: Tc-99m-Labeled Fab Fragment Anti-CEA Antibody (IMMU-4) for the Radioimmunodetection (RAID) of Colorectal Carcinoma. The Third Conference on Radioimmunodetection and Radioimmunotherapy of Cancer. November 15-17, 1990.
44. Li Z, Tian E, He J, **Ardalan B**, Hsia SL: Effects of liposomes made of purified lecithins on the growth of tumor cells in vitro and in vivo. AACR 32:432 (2573), 1991.
45. **Ardalan B**, Sridhar KS, Richman S, Benedetto P, Morrell L, Feun L, Savaraj N, Waldman S: Addition of high dose leucovorin (LV) to high dose infusion of 5-fluorouracil and low dose PALA: Effective in pancreatic cancer therapy. ASCO 10:139 (423), 1991.
46. Sridhar KS, Krishan A, Anac S, Duncan R, Benedetto P, **Ardalan B**, Samy T, Feun L, Savaraj N, Richman S: Phase I study of doxorubicin plus prochlorperazine as a resistance modified. ASCO 10:106 (294), 1991.
47. Tian E, Higashi Y, Yoshioka M, Ariyoshi M, Murakami T, Yatas N, **Ardalan B**: Modulation of 5-fluorouracil antitumor activity by uracil (Ura) in mice bearing colon adenocarcinoma 26: With biochemical correlation. AACR 32:414 (2465), 1991.
48. Morrell L, **Ardalan B**, Richman S, Waldman S, Feun L, Sridhar KS, Benedetto P: A phase II study of thiotepa (TP) in combination with 5-fluorouracil and leucovorin (LV) in patients with advanced breast cancer (BC). ASCO 10:62 (124), 1991.
49. **Ardalan B**, Sridhar KS, Reddy R, Benedetto P, Richman S, Waldman S, Morrell L, Feun L, Savaraj N, Livingstone A: Phase I and II study of high dose 5-fluorouracil and high dose leucovorin with low dose PALA in patients with advanced malignancies. Presented to the Seventh International Conference on Chemical Modifiers of Cancer Treatment, Feb 1991.
50. Serafini N, Vargas-Cuba R, Garrido J, Benedetto P, **Ardalan B**, Robinson D, Moffat F,

- Pinsky C: Clinical relevance of Tc-99m-Fab ~~CEA~~ monoclonal antibody (MoAb) in the early detection of recurrence of colorectal cancer. Amer. Assoc. for the Study of Liver Diseases. Louisiana, May 19-22, 1991.
51. **Ardalan B**, Donofrio K, Sridhar KS, Feun L, Savaraj N, Benedetto P, Morrell L, Waldman s, Reddy R, Livingstone A: Is there hope after 5-FU bolus? A phase II study of short term protracted infusion of high dose 5-fluorouracil(5-FU) with leucovorin (LV), and low dose phosphonacetyl-1-aspartic acid (PALA) in colorectal carcinoma. ASCO 11:186 (**558**), 1992.
  52. Tian E, **Ardalan B**, Benedetto P, Feun L, Morrell L, Waldman S, Hurley J, Savaraj N, Richman S, Livingstone A, Anac S: A phase II study of short term protracted infusion of high dose 5-fluorouracil (5-FU) with Leucovorin (LV) and low dose phosphonacetyl-L-aspartic acid (PALA) in pancreatic carcinoma. ASCO 11:184 (**550**), 1992.
  53. Kodali V, Reddy R, Parker T, Livingstone A, Levi J, **Ardalan B**, Benedetto P, Silva M, Jeffers L, Schiff E: Role of laparoscopy in pancreatico-biliary malignancy. ASGE, 1992 (Submitted).
  54. Molina E, Reddy R, Albanese A, Vargas C, Parker T, Jeffers L, Livingstone A, Levi J, **Ardalan B**, Silva M, Schiff ER: Diagnostic laparoscopy in patients with previous extensive abdominal surgery. ASGE, 1992 (Submitted).
  55. Morrell L, Richman S, Waldman S, Hurley J, Otrakji C, Sridhar KS, Benedetto P, Feun L, **Ardalan B**, Donofrio K, Liebman A, Hanlon J: Methotrexate, Vinblastine, Doxorubicin, Cisplatin (MVAC) as neoadjuvant for locally advanced breast cancer (LABC). ASCO 11:84 (162), 1992.
  56. Hung T, Angeles A, Tian E, **Ardalan B**: Detection of changes in the expression of thymidylate synthase (TS) gene in normal and malignant human tissues by RT-PCR. AACR 33:355 (2116),1992.
  57. Tian E, Ardalan K, Hochman I, Tejada F, **Ardalan B**: In vitro comparison of low dose 24 hr exposure vs high dose 1 hr exposure of a melanoma cell line to 5-fluorouracil (5FU), stimulating our clinical studies. AACR 33:545 (3260), 1992.
  58. Zheng JW, Chan KK, **Ardalan B**, Hengst J, Muggia FM: One hour exposure is not adequate for cytotoxic evaluation of some alkylating agents. AACR 33:403 (2408), 1992.
  59. Feun LG, Reddy KR, Yrizzary JM, Savaraj N, Guerra JJ, Purser RK, Waldman S, Moffat F, Morrell L, **Ardalan B**, and Benedetto P: Phase I hepatic chemoembolization trial with cisplatin and lipiodol. AACR 33: (1376), 1992.
  60. Serafini AN, Vargas-Cuba R, Moffat F, Benedetto P, **Ardalan B**, Dewanjee MK, DeJager R, Sfakianakis G: Radioimmunosintigraphy (RIS) of colorectal cancer with Tc-99m-IgG3 labeled whole human monoclonal antibody (Hm<sub>o</sub>Ab) 88bV59. The Society of Nuclear Medicine 40<sup>th</sup> Annual Meeting, Toronto, Canada, June 1993.
  61. Serafini AN, Varga-Cuba R, Moffat F, Benedetto P, **Ardalan B**, Dewanjee MK, Dejager R, Sfakianakis G: Radioimmunosintigraphy (RIS) of colorectal cancer with T<sub>c</sub>-99m-IgG<sub>3</sub> labeled whole human monoclonal antibody (HmoAb( 88BV59. Society of Nuclear Medicine 40<sup>th</sup>, Toronto 1993.
  62. Ucar A, Sridhar KS, **Ardalan, B**. Phase II trial of weekly bolus PALA and high dose 24 hr 5-fluorouracil (5-FU) infusion in advanced non-small cell lung cancer (NSCLC).
  63. Flores MR, Berlin N, Austin G, **Ardalan, B**: A new complication of permanent

- indwelling central venous catheter. ASCO 1993.
64. Tian E, Reddy KR, Livingstone A, **Ardalan, B.** A new predictive PCR assay for detecting normal and malignant tissue Thymidylate Synthase (T.S.) gene expression in patients with 5-fluorouracil (5-FU) resistance and colorectal cancer AACR 1993.
  65. **Ardalan B,** Donofrio K, Sridhar KS, Benedetto P, Waldman S, Richman S, Reddy R, Livingstone A. A phase II study of short-term protracted infusion of high dose 5-fluorouracil (5-FU) and leucovorin (LV) and low dose phosphonacetyl-L-aspartic acid (PALA) in treated and untreated colorectal carcinomas. ASCO 1993.
  66. Presant CA, Wolf N, Waluch V, **Ardalan, B,** Brechner R, Wiseman C, Blayney DW, Kennedy P and the Southwest Oncology Group (SWOG). Modulation of intratumoral (IT) 5-FU pharmacokinetics (PK) by leucovorin (LV) and methotrexate (M) documented by <sup>19</sup>F - magnetic resonance spectroscopy (MRS) initial results of SWOG studies 9006 and 9118. ASCO 1993.
  67. **Ardalan, B,** Reddy KR, Livingstone A, Tian E. Thymidylate synthase gene expression in normal and malignant gastrointestinal tissues in relation to in vivo response to 5-FU - based therapy, AACR 35:549, 1994.
  68. Tian E, Donofrio K, Sridhar KS, Feun LG, Morrell L, Richman SP, Benedetto P, Chatoor H, **Ardalan B.** Phase I study of 24 hr infusion of 5-fluoro-deoxyuridine (FUdR) with pharmacokinetics. AACR 35:244, 1994.
  69. Presant CA, Wolf W, Waluch V, **Ardalan B,** Kennedy P, Blayney D, Wiseman C. Modulation of intratumoral (IT) 5-FU pharmacokinetics (PK) in human gastrointestinal neoplasms by leucovorin (LV), interferon (IF) and methotrexate (MTX) - A <sup>19</sup>F (magnetic resonance spectroscopy study. ASCO, 13:199, 1994.
  70. **Ardalan B,** Ucar A, Reddy R, Livingstone A, Schwade J, Markoe A, Richman S, Donofrio K. Phase I trial of low dose PALA and high dose 5-fluorouracil (5-FU) as a short term infusion concomitantly with radiation therapy in the treatment of adenocarcinoma of the pancreas, ASCO, 13:215, 1994.
  71. Ucar A, Sridhar KS, Chatoor H, **Ardalan B.** Phase II trial of weekly low dose bolus PALA and high dose 24 hr 5-fluorouracil (5-FU) with high dose leucovorin (LV) infusion in advanced non-oat cell lung cancer, ASCO 13:351, 1994.
  72. **Ardalan B,** Donofrio K, Livingstone A, Reddy R, Richman S, Sridhar KS, Benedetto P, Morrell L, Miller CL, Feun L. A phase II study of weekly low dose bolus phosphonacetyl-L-aspartic acid (PALA) and 24 hr infusion with high-dose fluorouracil (FU) and leucovorin (LV) in colorectal cancer. ASCO 14:220, 1995.
  73. **Ardalan B,** Sridhar KS, Feun LG, Richman SP, Donofrio K, Watson C. Phase I study of 24-hour infusion of 5-fluorodeoxyuridine (FUdR), with pharmacokinetics. AACR 36:237, 1995.
  74. **Ardalan B,** Deng Z. Thymidylate synthase gene expression in normal and malignant colorectal tissues: Relation to in vivo response and survival. AACR 37:201, 1996.
  75. **Ardalan B,** Livingstone A, Deng Z, Sridhar KS, Feun L, Richman S, Sparling L, Triplett N. Phase I-II trial of high dose 24-hour infusion of fluorodeoxyuridine (FUdR) in patients with colorectal cancer (previously failed 5-flourouracil). ASCO 15:202, 1996.
  76. **Ardalan B,** Feun L, Reddy KR, Yrizarry JM, Guerra JJ, Bernstein D, Jeffers LJ, Livingstone A, Levi J, Savaraj N, Hurley J, Murray T, Scagnelli T. Phase II trial of lipiodol chemoembolization (LCE) with Cisplatin (DDP) and Thiotepa (TT) for

- unresectable liver tumors (LT). ASCO 15:211, 1996.
77. **Ardalan B**, Sparling L, Livingstone A, Francheschi D, Sridhar KS, Feun L, Richman S, Triplett N. Phase II trial of high-dose 24-hour infusion of 5-fluorodeoxyuridine (FUdR) in patients with inoperable pancreatic cancer (previously failed 5-FU and Gemzar)ASCO 16:282a, 1997.
  78. **Ardalan B**, Deng Z. Comparison of cytotoxicity of fluoropyrimidines in human colon adenocarcinoma DLD-1 cells: with clinical implications. AACR 39:435, 1998.
  79. **Ardalan B**, Bathe OF, Francheschi D, Livingstone A, Moffat F, Tian E. High levels of Thymidylate synthase gene expression predict a worse outcome following resection of hepatic metastases from colorectal carcinoma. ASCO 17:280a, 1998.
  80. **Ardalan B**, Bathe OF, Francheschi D, Livingstone A, Moffat F, Tian E. Increased Thymidylate Synthase gene expression in liver metastases from colorectal carcinoma: Implications for chemotherapeutic options and survival. American Radium Society Monaco, 1998.
  81. **Ardalan B**, Deng,Z.M 5-Flouro-2'-deoxyuridine induced apoptosis and decreased BCL-2 protein expression in cancer cell lines. AACR 1999
  82. **Ardalan B**, L. Sparling, K.S. Sridhar, J. Hurley, L. Feun, S. Richman, K. Hamilton. Phase II Trial of High Dose 24-hour Infusion of Fluorodeoxyuridine (FUdR) in Patients with Metastatic Colorectal Cancer (Previously failed multiple chemotherapeutic modalities.) ASCO 1999
  83. **Ardalan B**, B.G. Que- Enhanced Gene Expression of Thymidylate Synthase and Thymidine Kinase in Fluoropyrimidine-Resistant Human Colon Cancer Cell Line. AACR 2000
  84. **Ardalan B**, I.G. Kaklamanos, A.S. Livingstone, D. Franceschi, O.F. Bathe, T.D. Korensky, L. Sparling, M. J. Boyle - Neoadjuvant and Adjuvant Cisplatin, Paclitaxel (TAXOL), 5-fluoro-deoxyuridine (FUdR) and Leucovorin without Radiation for Operable Adenocarcinoma of the Esophagus and Stomach. ASCO 19:279a - 2000.
  85. **Ardalan B**, K. Ferry, A. Livingstone, D. Franceschi, P. Bejarano L. Sparling, K. Hamilton- Neoadjuvant and Adjuvant Cisplatin, Paclitaxel (Taxol, 5-Fluoro-Deoxyuridine (FUdR) and Leucovorin without Radiation for Advanced Operable Carcinoma of the Esophagus ASCO 20:159, 2001
  86. **Ardalan B**, K. Ferry A. Livingstone, D. Franceschi, P. Bejarano, L. Sparling, K. Hamilton – Neoadjuvant (NAD), adjuvant (AD) treatment without radiation in patients with advanced operable adenocarcinoma of esophagus. – ASCO 2002
  87. Abdulla A, Subbarayan PR & Ardalan B Standardization of a strategy to analyse tandem repeats in the 5'UTR of hTS gene, University of Miami, Department of Biology Undergraduate Research Seminar, Coral Gables, FL, USA - 2002
  88. Elena L. Paley, Subbarayan R. Pochi, **Ardalan B**. and Theodore J. Lampidis. -Hypoxia-Inducible Transcriptional factor -1 is associated with mitosis under normoxia and hypoxia. - 2004
  89. Subbarayan PR, Sarkar M, Nelson G. Shabashvili D & **Ardalan, B**. Akt1/PKB pathway is affected in 5-FU resistant HT-29 cells. American ASCO 95<sup>th</sup> Annual Meeting, March 27-31, Orlando, FL. - 2004
  90. Ramsay L, Subbarayan PR, Sarkar M and **Ardalan, B** A simple method to isolate genomic DNA from human whole blood and cultured cells, Zubard Memorial Lecture

and poster session, SCCC, Miami, FL, June 3, 2004.

91. J Parra, M Hickeson, **Ardalan, B**, A Ribeiro, A Livingstone, M. Lima and D Franceschi . Positron emission tomography (PET) in locally advanced esophageal cancer (EC) 2004
92. **Ardalan, B**, A Livingstone, D Franceschi, S Spector, G. Walker, A Burnett, P Ganjei-Azar, M Lima, L Sparling. Neoadjuvant (NAD), adjuvant (AD) treatment (without radiation) in patients with advanced operable adenocarcinoma of the esophagus. ASCO GI Symposium, San Francisco. -2004
93. **Ardalan, B**, A Livingstone, D. Franceschi, O. Kozyreva,, E. Santos , K-T. Tsai, M. Lima. A Phase II study of irinotecan, fluorouridine and leucovorin (IFLUX) as a first-line chemotherapy in advanced colorectal cancer.– ASCO GI Symposium, Hollywood, Florida – 2005j
94. Subbarayan PR, Lee P and **Ardalan, B** Inhibition of RNA synthesis by 5-fluorouridine accounts for its cito toxicity on colorectal cancer cells in vitro, American Association for Cancer Research 96th Annual Meeting, April 16-20, Anaheim, CA, USA – 2005
95. Subbarayan PR, Wang PG, Lampidis TJ, **Ardalan, B** and Braunschweiger P. Increased expression of Glut1 mRNA and protein levels correlates with increased sensitivity to glycol-conjugated nitric oxide donors in different cell types, American Association for Cancer Research 96th Annual Meeting, April 16-20, Anaheim, CA, USA – 2005
96. Subbarayan PR, Mayra Lima, Rizalina Olegario, Olga Kozyreva, Kelvin Lee, **Ardalan, B** Reversal of 5-FU resistance by arsenic trioxide-97th AACR Annual Meeting, Washington DC - 2006
97. Neoadjuvant and Adjuvant chemotherapy without radiation for Esophagela cancer- **Ardalan, B** MD, Seth A. Spector, MD, Alan S. Livingstone, MD, Dido Franceschi, MD, Parviz Ganjei-Azar, MD, Mayra Lima, ARNP, Lynn Sparling, RN, Gail Walker, PhD, Carol P. Bowen-Wells. – ASCO – GI Symposium, San Francisco 2006
98. Phase II trial of DJ-927, an oral tubulin depolymerization inhibitor, in the treatment of metastatic colorectal cancer. M.R. Moore, C. Jones, G. Harker, F. Lee, **Ardalan, B**, M.W Saif, P. Hoff, J. Coomes, C. Rollins K. Felt – ASCO 2006
99. Neoadjuvant and adjuvant chemotherapy without radiation for esophageal cancer. – **Ardalan, B** S. Spector, A.S. Livingstone, D. Franceschi, P. Ganjei-Azar, M. Lima, L. Sparling, G. Walker, C.P. Bowen-Wells – ASCO Annual Mtg, Atlanta 2006.
100. Subbarayan PR, Ramos Y, Mezentsev D, Bongato T, Ganjei-Azar P, Reis I, Kozyreva O, Lee K, **Ardalan, B** (2007), A Phase I study of 5-FU and arsenic trioxide for patients with refractory metastatic colorectal carcinoma, 2007 Gastrointestinal Cancers Symposium, ASCO-GI, Jan.19-21, 2007, Orlando, FL, USA.
101. **Ardalan, B**, Subbarayan PR, Sarkar M, Nelson G, and Benitez E, Chronic exposure of CRC cell line HT29 to 5-FU or FUR alters multiple independent pathways, American Association for Cancer Research 98th Annual Meeting, April 14-18, 2007, Los Angeles, CA, USA.
102. Subbarayan PR, Ramos Y, Mezentsev D, Bongato T, Ganjei-Azar P, Reis I, Kozyreva O, Lee K, **Ardalan, B** (2007), A Phase I study of 5-FU and arsenic trioxide for patients with refractory metastatic colorectal carcinoma, 2007 Gastrointestinal Cancers Symposium, ASCO-GI, Jan.19-21, 2007, Orlando, FL, USA.
103. **Ardalan, B**, S. Spector, D. Mezentsev, M. Milina, I. Reis, P. Ganjei-Azar, M. Sapp, J. Rios, D. Franceschi, A. Livingstone; Phase II study of neoadjuvant chemotherapy with



FUdR (F), Leucovorin (L), Oxaliplatin (O) and Docetaxel (D) (FLOD) in chemo-naive operable esophagogastric carcinoma, 2007 Gastrointestinal Cancers Symposium, ASCO-GI, Jan.25-27, 2008, Orlando, FL, USA.

104. S.R. Pochi, R. Yipsel, D.Mezentsev, P.Ganjei-Azar, I.Reis, K.Lee, **Ardalan, B**; A continued report on phase I study of escalating doses of 5-FU and arsenic trioxide in patients with refractory metastatic colorectal carcinoma; 2007 Gastrointestinal Cancers Symposium, ASCO-GI, Jan.25-27, 2008, Orlando, FL, USA.
105. Subbarayan PR, Ramos Y, Fernandez A, Gonzalez M, Mezentsev D, Bongato T, Ganjei-Azar P, Reis I, Lee K, **Ardalan, B** (2009), Phase I study of escalating doses of 5-FU and Arsenic Trioxide (As<sub>2</sub>O<sub>3</sub>) in patients with refractory metastatic colorectal carcinoma, American Association for Cancer Research 100th Annual Meeting, April 18-22, 2009, Denver, CO, USA. Abstract Number 3608.

**21. Other works accepted for publication: None**

**V. PROFESSIONAL**

**22. Funded Research Performed (include all grants received, identifying the principal investigator):**

Monsanto Chemical Company: A contract to study the mechanism of sensitivity or resistance of Carbetimer in vivo or in vitro. 06/01/84-05/30/86; **Bach Ardalan** (P.I.): \$240,000.

MAO/RFP No. NCI-CM-17364-15, Master Agreement No NO1-CM-376000.  
Preclinical Pharmacology Studies with Clomesone.  
01/01/86-11/31/87; **Bach Ardalan** (P.I.): \$88,914.

Monsanto Chemical Company, G.D. Searle:  
Further studies into the mechanism of action of Carbetimer.  
06/01/88-05/30/90; **Bach Ardalan** (P.I.): 140,000.

Warner-Lambert Company:  
To conduct Phase I study with 3-Deazaguanine  
and pharmacokinetics.  
06/01/88 to 5/30/90; **Bach Ardalan** (P.I.): 130,000.

Monsanto Chemical Company, G.D. Searle:  
Renewal of the further studies into the mechanism of  
action of Carbetimer.  
04/01/89-03/30/92; **Bach Ardalan** (P.I.): \$262,000.

RFP No. N01-CM-07343-22, Master Agreement No. N01-CM-07421. Phase I stud  
to evaluate biological response activity and potential antitumor activity of human  
interferon.

09/30/84-08/30/85; **Bach Ardalan** (P.I.): \$206,811.

NCI: RFA-CA-19-03

Pharmacodynamic correlates in advanced gastric cancer

12/01/91-11/30/94; **Bach Ardalan** (P.I.): \$253,568.

No. 16968 **Bach Ardalan** 4/24/03-2/10/10

Hoffman La Roche 162,100

An open-Label Randomize Phase III Study of Intermittent Oral Capecitabine in Combination with Intravenous Oxaliplatin (Q3W) (“XELOX”) versus Fluorouracil/Leucovorin as Adjuvant Therapy for Patients who have Undergone Surgery for Colon Carcinoma.

This is a pharmaceutical study seeking to compare the efficacy of oral xeloda and oxaliplatin with that of 5FU and leucovorin in the adjuvant colorectal cancer patients.

SCCC2003151 **Bach Ardalan** 8/2/04-12/31/07

Sanofi 150,300

A Non-Randomized Phase II Study: Feasibility and Outcome of Neo-Adjuvant Chemotherapy with Oxaliplatin, FUDR, Taxotere, and Leucovorin in the treatment of Previously Untreated Advanced Esophago-gastric Carcinoma.

This is a program designed by the P.I and sponsored by Sanofi. The goal of the program is to test whether our new combination of drugs listed could reduce the recurrence of distant metastases in this disease. Molecular marker correlation to toxicity and tumor response is included in the protocol.

14065 **Bach Ardalan** 10/5/04-3/31/08

Aventis 120,200

Phase II Study of weekly 24-Hour infusion 5-Fluor-Deoxyuridine (FUDR) Leucovorin with Oxaliplatin and Docetaxel (Taxotere) as a first-line treatment in patients with metastatic Gastric Adenocarcinoma.

This study was designed by the P.I and is sponsored by Aventis. The goal of the study is to test the efficacy of our new chemotherapy combination in advanced stomach cancer patients. Molecular marker correlation is also part of this study.

M0500609 **Bach Ardalan** 7/1/06-6/30/08

NIH-NCI \$500,000

Reversal of 5FU Resistance by Arsenic Trioxide in Colorectal Carcinoma.

### Active Research

McDonald Foundation pathways of cancer in esophageal adenocarcinoma

01/01/11 – 01/01/13 \$140,000

### New Application

1RO1CA149517-01A1 GRANT 10645561 5-FU Resistance Reversed by Arsenic Trioxide in Colorectal Cancer Phase II Trial, **Bach Ardalan** submission Complete pending Council Review 10/14/2010

**23. Editorial responsibilities:**

Reviewer for Cancer Treatment Reports; Cancer Research; Medical and Pediatric Oncology; Annals of Internal Medicine.

**24. Professional and Honorary Organizations (member; officer; date):**

1. Member of U.K. and American College of Physicians
2. Member of Royal Society of Medicine (U.K.)
3. Member of British Medical Association
4. American Association for Cancer Research
5. American Society of Clinical Oncology

**25. Honors and Awards:**

1. Visiting Professorship
2. Scientific Presentations, etc.
3. Invited Outside Lectureships

1. Presentation of Clinical and Basic Science Data at NCI, NIH in July and November, 1985.  
Biochemical Modulation Task Force.  
Interaction of PALA and 5-Fu.
2. American Association of Cancer Research and American Society of Clinical Oncology, May, 1985 High Pressure Liquid Chromatography Method in Quantitation of a New Anticancer Agent, 3-Deazaguanine.
3. California Hospital, October, 1985,  New Leads  
Colorectal Cancers
4. Kaiser Hospital, September, 1985  Adjuvant T  
Cancer
5. Chile-Internal Medicine, October 1990.  Role of C  
Carcinogenesis ,  Resist  
Mechanisms of Laboratory Evaluations and Clinical Usefulness ,  
Diagnosis/Treatment Prevention Early and Late Complete  
Chemotherapy

**26. Post-Doctoral Fellowships:**

1970-1971 Internship - King s College Hospital  
London, England

1971-1973	Residency -	King Edward Memorial Hospital, Ealing, England
1976-1978	Residency -	Oncology Fellow - Medicine, Georgetown University, Washington, D.C., USA

**TEACHING**

- 28. Teaching Awards Received:**
- 29. Teaching Specialization (Note briefly courses taught, new courses developed, innovative or experimental teaching, etc.)**
- 30. Thesis and Dissertation Advising/Post-doctoral student supervision (chairman or committee member; topic; student name; date):**

**Educational Courses:**

1990	Program director and organizer of an international course chemotherapeutic approaches in treatment of colorectal cancer 1990, Doral Ocean Beach Resort, Miami Beach, Florida.	<input type="checkbox"/> Novel 24, Feb. 23
------	---	---

**Teaching Responsibilities:**

1985-1986	House staff Teaching Clinical teaching of Medical Students Oncology Clinic and Diabetes Ward, Georgetown and USC Medical Center
1992-present	Clinical teacher 2 <sup>nd</sup> year, medical student at University of Miami

**VII. SERVICE**

**31. University Committee and Administrative Responsibilities:**

Chairman, Pharmacy and Therapeutics Committee at  
Norris Cancer Hospital and Research Institute  
Director, Grant Review Committee at USC Cancer Center  
Member, Selection Committee for the selection of the Director of Drug Development.  
Member, Selection Committee for Interns at LAC-USC Medical Center

**32. Community Activities.**